TALZENNA® (talazoparib) | Homepage

This site is intended only for healthcare professionals resident in the Republic of Ireland

Log out

Our medicines

Therapy areas

Explore content

Materials

Videos

Podcasts

Let’s connect

Let's connect

About

TALZENNA MoA

Talzenna MoA

gBRCA testing

Identifying patients

Guidelines

Study design

Baseline characteristics

Efficacy & Safety

TALZENNA efficacy

Primary endpoint & subgroup analysis

Secondary endpoints: ORR

Secondary endpoint: OS

Exploratory endpoints: DoR & TTR

TALZENNA safety

Safety and tolerabillity

Adverse events

Patient-reported outcomes with TALZENNA

Patient-reported outcomes

GHS/QoL

Breast symptoms

Dosing

Dose recommendation and special populations

Dose modifications/management

Patient Profiles

Support & Resources

Materials

Elevate

Personalising Breast Cancer Treatment

Understanding and Optimising PARP Inhibitors for mBC

PARP Inhibitors in mBC: the role of Real World Evidence

Now you can give them more

TALZENNA^® is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.¹

Please see full Prescribing Information and Patient Information.

TALZENNA^® is a proven alternative to chemotherapy* – with greater efficacy in a convenient, once-daily oral dose¹

TALZENNA^®significantly prolonged median progression-free survival (PFS) vs chemotherapy: 8.6 vs 5.6 months (HR=0.54 [95% CI: 0.41-0.71]; P<0.0001)¹

Find out more

Improved patient-reported outcomes

Significant improvements in GHS/QoL and breast symptoms²

See the results

Manageable safety profile

AEs were manageable with a low discontinuation rate¹

Review safety

Convenient, once-daily oral dosing

One dose once a day with or without food¹

Learn more

AE=adverse event; BRCA=breast cancer susceptibility gene; CI=confidence interval; GHS=global health status; HER2-=human epidermal growth factor receptor 2 negative; HR=hazard ratio; QoL=quality of life.

*Capecitabine, eribulin, gemcitabine, or vinorelbine.

References:

TALZENNA^® Summary of Product Characteristics.

Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: ﬁnal overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526-1535.

Legal Category: S1A
Further information is available upon request

PP-TAL-IRL-0106 May 2024

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Account

Log out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

PP-UNP-IRL-0784. June 2024

You are now leaving PfizerPro

You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0784. June 2024